Videos

Independent urology faces stagnant Medicare pay, rising costs, prior auth burden, and consolidation pressure, Celeste Kirschner, CAE, MHSA, says.

John P. Sfakianos, MD, discusses the challenges of managing recurrent LG-IR-NMIBC and the role of chemoablation.

Rising patient interest in TRT, GLP-1s, and peptide stacking requires clinicians to anchor conversations in evidence tiers, use baseline DEXA scans to monitor body composition, and engage patient goals without endorsing unsupported claims.

The data are compelling, but only if patients reach a medical oncologist. Joshua J. Meeks, MD, PhD, tackles the unresolved questions in MIBC care and lays out the referral steps every community urologist can take today.

With the recent FDA approval of enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) in MIBC, Joshua J. Meeks, MD, PhD, maps the treatment timeline patients should expect and the skin reactions that warrant an urgent referral.

For the first time in 25 years, a nonplatinum regimen beats cisplatin-based chemotherapy head-to-head. Joshua J. Meeks, MD, PhD, breaks down the KEYNOTE-B15/EV-304 data driving that shift.

A single FDA update just erased the platinum-eligibility line dividing patients with MIBC. Joshua J. Meeks, MD, PhD, explains what changed on July 10 and why a new subcutaneous option could ease access for rural patients

NeoBLAST, a phase 2/3 Canadian trial, tests whether active surveillance can safely replace surgery/radiation in MIBC patients with complete response to neoadjuvant therapy.

The data behind hyaluronic acid rectal spacers go well beyond the pivotal trial—3-year follow-up and real-world safety reviews add up to a compelling durability story.

As dose escalation and hypofractionation become the norm, 2 physicians break down why perirectal spacing has become essential and how hyaluronic acid and hydrogel products actually differ in the room.

Martin Schoen, MD, PhD, discusses key factors clinicians should consider when interpreting comparative real-world evidence for ARPI selection.

LUGPA CEO Celeste Kirschner, CAE, MHSA, outlines the association's top 2027 priorities: fee schedule reform, site-neutral payments, prior authorization, and practice consolidation.

Martin Schoen, MD, PhD, discusses how clinicians can interpret comparative real-world evidence and indirect analyses when head-to-head ARPI data are unavailable.

Prof Declan Murphy discusses PROTEUS pathologic responses with apalutamide plus ADT and their implications for future treatment strategies.

Closing out the discussion, Mark D. Tyson II, MD, MPH, and Alexandra Drakaki, MD, talk tumor boards as an underused coordination tool, and Tyson shares where his comfort level stands on the newly approved durvalumab (Imfinzi)-BCG combination.

How urologists partner with oncologists to deliver durvalumab plus BCG for high‑risk bladder cancer—keeping care local through communication.

From same-day texts to shared clinic visits, 2 academic physicians describe the day-to-day mechanics of a urology-medical oncology partnership that actually works for patients.

Mark D. Tyson II, MD, MPH, and Alexandra Drakaki, MD, work through what the POTOMAC results mean for who should actually receive the combination.

Timothy D. McClure, MD, discusses 2-year PRESERVE trial safety data and 12-month AUA findings linking prostate size to IPSS improvement after focal IRE.

Mary Dunn, MSN, RN, NP-C, OCN, discusses how APPs support genetic testing through patient counseling, test ordering, result communication, and referrals to genetics specialists.

University of Florida urology chiefs Miranda Eubank, MD; Trisha Nguyen, MD; and Jordan Matthews-Smith, MD, reflect on residency milestones, mentorship, community, and lessons learned along the way.

In this Urology Times Special Report series, Mark D. Tyson II, MD, MPH discusses high-risk non–muscle invasive bladder cancer (NMIBC) with Alexandra Drakaki, MD.

Emanuele Crupi, MD, discusses prospective data supporting GemFLP as a benchmark for treatment of advanced urachal and non-urachal urinary tract adenocarcinomas.

Nicole L. Miller, MD, FACS, discusses how to distinguish bladder dysfunction from persistent obstruction when evaluating LUTS after BPH treatment.

Davis Viprakasit, MD, FACS, discusses advanced cystoscopy training for APPs and the importance of collaboration between APPs and urologists to expand patient care.

María Natalia Gandur Quiroga, MD, MSc, highlights treatment selection, negative trials, and implementation in GU oncology as 3 key themes emerging from ASCO 2026.

Kari Tikkinen, MD, PhD, discusses POISE-3 findings showing tranexamic acid reduced major bleeding without significantly increasing thrombotic events in urologic surgery.

Mary Dunn, MSN, NP-C, OCN, RN, highlights advances in advanced prostate cancer, including earlier systemic therapy, PSMA-PET, and PARP inhibitors.

In this video, Scott Sellinger, MD, FACS, discusses factors beyond the presence of PTEN deficiency that may influence how clinicians approach capivasertib (Truqap) treatment in metastatic hormone-sensitive prostate cancer.

Scott Bauer, MD, ScM, discusses an N-of-1 trial showing heterogeneous responses to long-term tamsulosin, identifying older men who may be candidates for deprescribing.